T
Tom Claeys
Researcher at Ghent University Hospital
Publications - 22
Citations - 1339
Tom Claeys is an academic researcher from Ghent University Hospital. The author has contributed to research in topics: Prostate cancer & Biochemical recurrence. The author has an hindex of 8, co-authored 21 publications receiving 937 citations. Previous affiliations of Tom Claeys include Ghent University.
Papers
More filters
Journal ArticleDOI
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost,Dries Reynders,Karel Decaestecker,Valérie Fonteyne,Nicolaas Lumen,Aurélie De Bruycker,Bieke Lambert,Louke Delrue,Renée Bultijnck,Tom Claeys,Els Goetghebeur,Geert Villeirs,Kathia De Man,Filip Ameye,Ignace Billiet,Steven Joniau,Friedl Vanhaverbeke,Gert De Meerleer +17 more
TL;DR: ADT-free survival was longer with MDT than with surveillance alone for oligorecurrent PCa, suggesting that MDT should be explored further in phase III trials.
Journal ArticleDOI
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
Karel Decaestecker,Gert De Meerleer,Bieke Lambert,Louke Delrue,Valérie Fonteyne,Tom Claeys,Filip De Vos,Wouter Huysse,Arne Hautekiet,Gaethan Maes,Piet Ost +10 more
TL;DR: Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation therapy with 2 years without grade III toxicity.
Journal ArticleDOI
Age-related differences in metabolites in the posterior cingulate cortex and hippocampus of normal ageing brain: A 1H-MRS study
Harmen Reyngoudt,Tom Claeys,Leslie Vlerick,Stijn E. Verleden,Marjan Acou,Karel Deblaere,Yves De Deene,Yves De Deene,Kurt Audenaert,Kurt Audenaert,Ingeborg Goethals,Eric Achten +11 more
TL;DR: In this paper, Proton magnetic resonance spectroscopy (1H-MRS) was performed in the posterior cingulate cortex (PCC) and the left hippocampus (HC) of 90 healthy subjects.
Journal ArticleDOI
Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
Aurélie De Bruycker,Bieke Lambert,Tom Claeys,Louke Delrue,Chamberlain Mbah,Gert De Meerleer,Geert Villeirs,Filip De Vos,Kathia De Man,Karel Decaestecker,Valérie Fonteyne,Nicolaas Lumen,Filip Ameye,Ignace Billiet,Steven Joniau,Friedl Vanhaverbeke,W. Duthoy,Piet Ost +17 more
TL;DR: To describe the anatomical patterns of prostate cancer recurrence after primary therapy and to investigate if patients with low‐volume disease have a better prognosis as compared with their counterparts.
Journal ArticleDOI
Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time
Bert Dhondt,Bert Dhondt,Elise De Bleser,Tom Claeys,Sarah Buelens,Nicolaas Lumen,Jo Vandesompele,Anneleen Beckers,Valérie Fonteyne,Kim Van der Eecken,Aurélie De Bruycker,Jérôme Paul,Pierre Gramme,Piet Ost +13 more
TL;DR: Although PC patients with oligometastatic disease had a more favorable prognosis, no serum-derived biomarkers allowing for prospective discrimination of oligo- and polymetastatic prostate cancer patients could be identified.